Analyst Price Targets — TTI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 12, 2026 10:48 am | Stephen Gengaro | Stifel Nicolaus | $13.00 | $9.87 | StreetInsider | TETRA Technologies Inc. (TTI) PT Raised to $13 at Stifel, 'remains a favorite name' |
| December 31, 2025 2:32 pm | — | Northland Securities | $11.50 | $9.44 | TheFly | Tetra Technologies price target raised to $11.50 from $8.50 at Northland |
| October 30, 2025 12:33 pm | Bobby Brooks | Northland Securities | $8.50 | $7.01 | TheFly | Tetra Technologies price target raised to $8.50 from $8 at Northland |
| October 15, 2025 10:53 am | Stephen Gengaro | Stifel Nicolaus | $9.00 | $7.04 | TheFly | Tetra Technologies price target raised to $9 from $6.50 at Stifel |
| September 26, 2025 1:25 pm | — | Northland Securities | $7.00 | $6.02 | TheFly | Tetra Technologies price target raised to $7 from $5.50 at Northland |
| April 15, 2025 12:25 pm | Stephen Gengaro | Stifel Nicolaus | $6.50 | $2.30 | TheFly | Tetra Technologies price target lowered to $6.50 from $7 at Stifel |
| June 14, 2022 11:15 am | Tim Moore | EF Hutton | $8.00 | $4.84 | Pulse 2.0 | TETRA Technologies (TTI) Stock Price: $8 Target And Buy Rating |
Latest News for TTI
San Diego, California--(Newsfile Corp. - April 16, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biopharmaceutical company developing sulfur-based prodrugs designed as precursors to thiol-active compounds such as cysteamine, today announced that management will present at the 2026 Bloom Burton & Co. Healthcare Investor Conference, taking place in…
SPRING, Texas, April 7, 2026 /PRNewswire/ -- TETRA Technologies, Inc. (NYSE:TTI) will release First Quarter 2026 results after the market closes on April 29, 2026. Brady Murphy, President and CEO, and Matt Sanderson, CFO, will host a conference call to discuss the results and outlook on April 30, 2026, at 10:30am ET.
For the second-straight year and third time in five years, the Dow, S&P 500, and Nasdaq started off the calendar with quarterly losses. ‘Didn't get off the bus,' is the apt sports colloquial that comes to mind.
Allspring Global Investments Holdings LLC acquired a new position in shares of Tetra Technologies, Inc. (NYSE: TTI) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 788,253 shares of the oil and gas company's stock, valued at approximately $7,386,000. Allspring Global Investments Holdings LLC owned 0.59%
Results from healthy volunteer study of next-generation STAT3 inhibitor, TTI-109, on track for Q2 2026 Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) are anticipated in H2 2026 Cash runway expected to be sufficient to fund operations into Q4 2026 after clinical readouts HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TTI.
U.S. House Trading
No House trades found for TTI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.